Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.

Christoph OingMarcus HentrichAnja LorchDietrich GläserHolger RumpoldSebastian OchsenreitherStephan RichterAnnette DieingStefanie ZschäbitzRonnie Rodrigues PereiraCarsten BokemeyerChristoph Seidel

Published in: Journal of cancer research and clinical oncology (2019)

In this case series, cabazitaxel showed limited activity in heavily pre-treated GCT patients. Two-phase II studies are underway (NCT02115165, NCT02478502) prospectively assessing cabazitaxel in multiply relapsed GCTs.

Keyphrases

germ cell
phase ii
end stage renal disease
clinical trial
newly diagnosed
ejection fraction
chronic kidney disease
acute lymphoblastic leukemia
peritoneal dialysis
prognostic factors
hodgkin lymphoma
replacement therapy
patient reported